Gavi to Drop Mercury in Vaccines for 72M Children, Unlocking $600M in US Aid

For healthcare leaders and policymakers, this development underscores the complex intersection of vaccine safety, global health equity, and the use of taxpayer funds. The U.S. stance could pressure other donors to reconsider the acceptibility of thimerosal-preserved vaccines overseas, potentially reshaping decades-old procurement norms. But the sudden policy shift also raises urgent questions about the scientific rationale, the risk of supply disruptions, and how to communicate safety without fueling vaccine hesitancy.

The Trump administration announced on July 29, 2026, that Gavi, the Vaccine Alliance, has committed to transitioning away from vaccines containing mercury, unlocking $600 million in previously congressionally approved U.S. funding. The joint announcement by the State and Health and Human Services Departments marks a sharp policy intervention, directly linking U.S. financial support to the elimination of thimerosal—a mercury-based preservative—from vaccines distributed to low- and middle-income countries. HHS Secretary Robert F. Kennedy, Jr., framed the move as an overdue correction to what he described as "glaringly racist policies" that exposed children in Africa and Asia to a "potent neurotoxin" while children in the U.S. and Europe had been protected for decades.

“

The Trump administration announced on July 29, 2026, that Gavi, the Vaccine Alliance, has committed to transitioning away from vaccines containing mercury, unlocking $600 million in previously congressionally approved U.S.

The scientific and regulatory context is crucial. Thimerosal (ethylmercury) has been used since the 1930s to prevent bacterial contamination in multi-dose vials, dramatically reducing vaccine costs and enabling mass immunization programs. The U.S. and European Union began phasing it out of most pediatric vaccines approximately 25 years ago as a precautionary measure, even though large-scale studies by the World Health Organization and the Institute of Medicine found no evidence of harm from the low levels used in vaccines. The CDC’s Advisory Committee on Immunization Practices (ACIP) formally stopped recommending any thimerosal-containing vaccines in 2025, reflecting the complete domestic shift. However, Gavi’s supply chains—heavily reliant on affordable multi-dose vials—continued to include pentavalent (DTP-Hib-HepB) and meningococcal A vaccines preserved with thimerosal, reaching more than 72 million children annually, predominantly in Africa and Asia.

The Trump administration’s deal, secured through direct negotiations, represents a significant pivot in global health diplomacy. The U.S. had been withholding $600 million in congressionally appropriated funds for Gavi, leveraging the funding to extract safety reforms. Under the agreement, Gavi will “make every effort” to transition meningococcal A vaccines to mercury-free products that also cover additional strains, and to shift the pentavalent vaccine to a mercury-free hexavalent formulation that includes added protection. This transition will require substantial manufacturing scale-up, regulatory approvals, and possibly higher per-dose costs, which Gavi and its partners must absorb. The administration’s narrative casts this as a triumph for health equity and transparency, but it also reflects a broader political skepticism toward established vaccine safety science, championed by Secretary Kennedy throughout his career.